6311-47-3

Basic information

• Product Name: 5-bromo-2-nitro-N-phenyl-aniline
• Synonyms: 5-bromo-2-nitro-N-phenyl-aniline;BenzenaMine, 5-broMo-2-nitro-N-phenyl-
• CAS NO: 6311-47-3
• Molecular Formula: C₁₂H₉BrN₂O₂
• Molecular Weight: 293.13
• Mol File: 6311-47-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 382.6 °C at 760 mmHg
• Flash Point: 185.2 °C
• Appearance: /
• Density: 1.597 g/cm³
• Vapor Pressure: 4.66E-06mmHg at 25°C
• Refractive Index: 1.686
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5-bromo-2-nitro-N-phenyl-aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-nitro-N-phenyl-aniline(6311-47-3)
• EPA Substance Registry System: 5-bromo-2-nitro-N-phenyl-aniline(6311-47-3)

Safety Data

• Hazardous Substances Data: 6311-47-3(Hazardous Substances Data)

Usage

General Description

5-bromo-2-nitro-N-phenyl-aniline is a chemical compound with the molecular formula C12H8BrN3O2. It is a yellow-orange solid with a molecular weight of 308.12 g/mol. 5-bromo-2-nitro-N-phenyl-aniline is used as a reagent in organic synthesis and pharmaceutical research, particularly in the development of pharmaceuticals and agrochemicals. It has been found to have potential anti-tumor and anti-cancer properties, and has been studied for its potential use in cancer therapy. Additionally, 5-bromo-2-nitro-N-phenyl-aniline is used as an intermediate in the synthesis of various organic compounds, and its properties make it a valuable tool for researchers in the fields of chemistry and medicine.

InChI:InChI=1/C12H9BrN2O2/c13-9-6-7-12(15(16)17)11(8-9)14-10-4-2-1-3-5-10/h1-8,14H

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 62-53-3 aniline 
• 51686-78-3 2,4-dibromonitrobenzene 
• 610-38-8 4-bromo-1,2-dinitrobenzene 

Downstream Products

• 1116091-02-1 C₂₀H₁₄N₂O₂ 
• 1616096-79-7 1-(3,4-dihydroisoquinolin-2(1H)-yl)-3-(3-(1-phenyl-1H-benzo[d]imidazol-6-yl)phenoxy)propan-2-ol 
• 343952-87-4 5-bromo-N¹-phenylbenzene-1,2-diamine 
• 1396778-99-6 (2,6-dimethyl-4-(4-nitro-3-(phenylamino)phenyl)piperazin-1-yl)(phenyl)methanone 
• 1396780-27-0 5-(3,5-dimethylpiperazin-1-yl)-2-nitro-N-phenylaniline 

Relevant articles and documents

Benzimidazolone derivatives organic light emitting compound and organic electroluminescent device including the same

Provided is a benzo imidazolone derivative organic electroluminescent compound represented by chemical formula a. Chemical Formula a. The benzo imidazolone derivative organic light emitting compound is suitable for inclusion in an organic electroluminescent device. Both electrochemical stability and thermal stability can be satisfactorily met.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives

The dysfunction and mutual compensatory activation of RAF-MEK-ERK and PI3K-PDK1-AKT pathways have been demonstrated as the hallmarks in several primary and recurrent cancers. The strategy of concurrent blocking of these two pathways shows clinical merits on effective cancer therapy, such as combinatory treatments and dual-pathway inhibitors. Herein, we report a novel prototype of dual-pathway inhibitors by means of merging the core structural scaffolds of a MEK1 inhibitor and a PDK1 inhibitor. A library of 43 compounds that categorized into three series (Series I–III) was synthesized and tested for antitumor activity in lung cancer cells. The results from structure-activity relationship (SAR) analysis showed the following order of antitumor activity that 3-hydroxy-5-(phenylamino) indolone (Series III) > 3-alkenyl-5-(phenylamino) indolone (Series I) > 3-alkyl-5-(phenylamino) indolone (Series II). A lead compound 9za in Series III showed most potent antitumor activity with IC50 value of 1.8 ± 0.8 μM in A549 cells. Moreover, antitumor mechanism study demonstrated that 9za exerted significant apoptotic effect, and cellular signal pathway analysis revealed the potent blockage of phosphorylation levels of ERK and AKT in RAF-MEK-ERK and PI3K-PDK1-AKT pathways, respectively. The results reported here provide robust experimental basis for the discovery and optimization of dual pathway agents for anti-lung cancer therapy.